HIMS

Over the past six months, Hims & Hers Health, Inc. stock has experienced significant fluctuations. The stock was up 10.21% for the day on May 8, 2026, but has seen a decline of 30.61% over the past six months. The FDA's move to exclude key GLP-1 drugs from its bulk compounding list put pressure on Hims & Hers Health's compounded weight-loss offerings, contributing to a significant drop in shares. In response, Hims & Hers has been leaning into partnerships for branded GLP-1 medications, including a deal with Novo Nordisk. The stock showed some positive momentum, being up 37.6% over the 30 days leading up to May 6, 2026, and a notable event was a single largest opening gap of +46.8% on March 9, 2026.